- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02180867
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Study Overview
Status
Conditions
- Leiomyosarcoma
- Fibrosarcoma
- Liposarcoma
- Mesenchymal Chondrosarcoma
- Stage III Soft Tissue Sarcoma AJCC v7
- Stage IV Soft Tissue Sarcoma AJCC v7
- Malignant Peripheral Nerve Sheath Tumor
- PEComa
- Synovial Sarcoma
- Epithelioid Sarcoma
- Alveolar Soft Part Sarcoma
- Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Myxofibrosarcoma
- Inflammatory Myofibroblastic Tumor
- Angiomatoid Fibrous Histiocytoma
- Extraskeletal Myxoid Chondrosarcoma
- Sclerosing Epithelioid Fibrosarcoma
- Atypical Fibroxanthoma
- Clear Cell Sarcoma of Soft Tissue
- Epithelioid Malignant Peripheral Nerve Sheath Tumor
- Extraskeletal Osteosarcoma
- Fibrohistiocytic Neoplasm
- Intimal Sarcoma
- Liver Embryonal Sarcoma
- Low Grade Fibromyxoid Sarcoma
- Low Grade Myofibroblastic Sarcoma
- Malignant Cutaneous Granular Cell Tumor
- Malignant Triton Tumor
- Myxoid Chondrosarcoma
- Myxoinflammatory Fibroblastic Sarcoma
- Nerve Sheath Neoplasm
- Pericytic Neoplasm
- Plexiform Fibrohistiocytic Tumor
- Skin Glomus Tumor
- Stage IB Soft Tissue Sarcoma AJCC v7
- Stage IIB Soft Tissue Sarcoma AJCC v7
Detailed Description
PRIMARY OBJECTIVES:
I. To identify the dose of pazopanib that is feasible when given in combination with radiation or chemoradiation in pediatric and adult patients newly diagnosed with unresected intermediate- and high-risk non rhabdomyosarcoma soft tissue sarcomas (NRSTS).
II. To compare the rates of near complete pathologic response (> 90% necrosis) with the addition of pazopanib to preoperative chemoradiation versus preoperative chemoradiation alone for potentially resectable > 5 cm, grade 2 or 3 intermediate to high risk chemotherapy-sensitive NRSTS in the phase II portion of the study for this cohort.
III. To compare the rates of near complete pathologic response (> 90% necrosis) with the addition of pazopanib to preoperative radiotherapy versus preoperative radiotherapy alone for potentially resectable intermediate to high risk adult and pediatric NRSTS in the phase II portion of the study for this cohort (using a phase II decision rule to go onto the phase III portion of the study).
IV. To compare the rates of event-free survival (EFS) with the addition of pazopanib to preoperative radiotherapy versus preoperative radiotherapy alone for localized intermediate to high risk adult and pediatric NRSTS in the phase III portion of the study for this cohort if the phase II decision rule is passed.
SECONDARY OBJECTIVES:
I. To estimate the rates of local failure, regional failure, distant metastasis free survival, disease-free survival, and overall survival with the addition of pazopanib to preoperative chemoradiation or preoperative radiation in intermediate to high risk adult and pediatric NRSTS.
II. To compare the pattern of recurrence (local, regional and distant) between preoperative chemoradiation or radiation with the addition of pazopanib for adult and pediatric NRSTS.
III. To define the toxicities of ifosfamide and doxorubicin chemotherapy and radiation when used in combination with pazopanib in intermediate to high risk adult and pediatric NRSTS.
IV. To define the toxicities of preoperative radiotherapy when used in combination with pazopanib in intermediate to high risk adult and pediatric NRSTS.
EXPLORATORY OBJECTIVES:
I. To gain insight into the disease biology of childhood and adult NRSTS through analysis of actionable mutations and whole genome sequencing.
II. To determine if microvessel density and circulating tumor deoxyribonucleic acid (DNA) predict response to pazopanib and outcome.
III. To determine the effect of pazopanib on doxorubicin exposure in children and adults with NRSTS.
IV. To evaluate change in fludeoxyglucose F 18 (FDG) positron emission tomography (PET) maximum standard uptake value (SUVmax) from baseline to week 10 or 13 in patients with unresected tumors and to correlate this change with pathologic response and EFS.
V. To compare the rate of response by standard imaging and pathologic assessment to determine which correlates better with local tumor control, distant tumor control, EFS, and overall survival.
OUTLINE: This study starts as a dose-escalation study of pazopanib.
CHEMOTHERAPY COHORT: Patients eligible for chemotherapy cohort are randomized to 1 of 2 treatment regimens.
REGIMEN A:
INDUCTION PHASE: Patients receive pazopanib orally (PO) once daily (QD) on weeks 1-12, ifosfamide intravenously (IV) over 2-4 hours on days 1-3 on weeks 1, 4, 7, 10, and doxorubicin IV over 1-15 minutes on days 1-2 on weeks 1 and 4. At least 24 hours after the completion of week 4 doxorubicin, patients undergo radiation therapy on weeks 4-10.
SURGERY: Patients undergo surgery on week 13.
CONTINUATION PHASE: Patients receive pazopanib PO QD on weeks 16-25, ifosfamide IV over 2-4 hours on days 1-3 on weeks 16 and 19, and doxorubicin IV over 1-15 minutes on days 1-2 on weeks 16, 19, and 22. If applicable, patients undergo additional radiation therapy at week 16
REGIMEN B:
INDUCTION PHASE: Patients receive ifosfamide IV over 2-4 hours on days 1-3 on weeks 1, 4, 7, 10 and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 1 and 4. At least 24 hours after the completion of week 4 doxorubicin, patients undergo radiation therapy on weeks 4-10.
SURGERY: Patients undergo surgery on week 13.
CONTINUATION PHASE: Patients receive ifosfamide IV over 2-4 hours on days 1-3 on weeks 16 and 19 and doxorubicin IV over 1-15 minutes on days 1-2 on weeks 16, 19, and 22. If applicable, patients undergo additional radiation therapy at week 16.
NON-CHEMOTHERAPY COHORT: Patients eligible for non-chemotherapy cohort are randomized to 1 of 2 treatment regimens.
REGIMEN C:
INDUCTION PHASE: Patients receive pazopanib PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.
SURGERY: Patients undergo surgery on week 10.
CONTINUATION PHASE: Patients receive pazopanib PO QD on weeks 13-25. If applicable, patients undergo additional radiation therapy at week 13.
REGIMEN D:
INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.
SURGERY: Patients undergo surgery on week 10.
CONTINUATION PHASE: If applicable, patients undergo additional radiation therapy at week 13.
After completion of study treatment, patients are followed up at 6, 12, 18, 24, 30, 36, 48, and 60 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Newfoundland and Labrador
-
Saint John's, Newfoundland and Labrador, Canada, A1B 3V6
- Janeway Child Health Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
London, Ontario, Canada, N6A 5W9
- Children's Hospital
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Montreal, Quebec, Canada, H2L 4M1
- CHUM - Hopital Notre-Dame
-
Montreal, Quebec, Canada, H2X 3E4
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
Montreal, Quebec, Canada, H1T 2M4
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
-
-
-
-
San Juan, Puerto Rico, 00926
- University Pediatric Hospital
-
San Juan, Puerto Rico, 00912
- San Jorge Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham Cancer Center
-
Birmingham, Alabama, United States, 35233
- Children's Hospital of Alabama
-
Birmingham, Alabama, United States, 35243
- The Kirklin Clinic at Acton Road
-
-
Alaska
-
Anchorage, Alaska, United States, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, United States, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, United States, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, United States, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, United States, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, United States, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, United States, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, United States, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, United States, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, United States, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Anaheim, California, United States, 92806
- Kaiser Permanente-Anaheim
-
Bakersfield, California, United States, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Burbank, California, United States, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Downey, California, United States, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, United States, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, United States, 92354
- Loma Linda University Medical Center
-
Long Beach, California, United States, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, United States, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, United States, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Los Angeles, California, United States, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, United States, 90048
- Cedars Sinai Medical Center
-
Los Angeles, California, United States, 90033
- Los Angeles General Medical Center
-
Madera, California, United States, 93636
- Valley Children's Hospital
-
Oakland, California, United States, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, United States, 94611
- Kaiser Permanente-Oakland
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, United States, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, United States, 94304
- Lucile Packard Children's Hospital Stanford University
-
Riverside, California, United States, 92505
- Kaiser Permanente-Riverside
-
Sacramento, California, United States, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, United States, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, United States, 92123
- Rady Children's Hospital - San Diego
-
San Diego, California, United States, 92120
- Kaiser Permanente-San Diego Zion
-
San Francisco, California, United States, 94158
- UCSF Medical Center-Mission Bay
-
San Marcos, California, United States, 92078
- Kaiser Permanente-San Marcos
-
San Rafael, California, United States, 94903
- Kaiser San Rafael-Gallinas
-
Torrance, California, United States, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Truckee, California, United States, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
Aurora, Colorado, United States, 80045
- UCHealth University of Colorado Hospital
-
Colorado Springs, Colorado, United States, 80909
- UCHealth Memorial Hospital Central
-
Denver, Colorado, United States, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Fort Collins, Colorado, United States, 80524
- Poudre Valley Hospital
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
Washington, District of Columbia, United States, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Deerfield Beach, Florida, United States, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Fort Myers, Florida, United States, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, United States, 32610
- University of Florida Health Science Center - Gainesville
-
Hollywood, Florida, United States, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, United States, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, United States, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, United States, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, United States, 32827
- Nemours Children's Hospital
-
Orlando, Florida, United States, 32803
- AdventHealth Orlando
-
Pensacola, Florida, United States, 32504
- Nemours Children's Clinic - Pensacola
-
Saint Petersburg, Florida, United States, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
Tampa, Florida, United States, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, United States, 33407
- Saint Mary's Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta - Egleston
-
Augusta, Georgia, United States, 30912
- Augusta University Medical Center
-
Savannah, Georgia, United States, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, United States, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, United States, 96819
- Kaiser Permanente Moanalua Medical Center
-
-
Idaho
-
Boise, Idaho, United States, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, United States, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, United States, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, United States, 83686
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, United States, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Chicago, Illinois, United States, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, United States, 60612
- University of Illinois
-
Chicago, Illinois, United States, 60611
- Lurie Children's Hospital-Chicago
-
Geneva, Illinois, United States, 60134
- Northwestern Medicine Cancer Center Delnor
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, United States, 62864
- Good Samaritan Regional Health Center
-
New Lenox, Illinois, United States, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
Oak Lawn, Illinois, United States, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, United States, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, United States, 61637
- Saint Jude Midwest Affiliate
-
Springfield, Illinois, United States, 62781
- Memorial Medical Center
-
Springfield, Illinois, United States, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, United States, 62702
- Saint John's Hospital
-
Warrenville, Illinois, United States, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, United States, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Richmond, Indiana, United States, 47374
- Reid Health
-
-
Iowa
-
Des Moines, Iowa, United States, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, United States, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, United States, 50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines, Iowa, United States, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, United States, 50316
- Iowa Lutheran Hospital
-
Iowa City, Iowa, United States, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Sioux City, Iowa, United States, 51101
- Siouxland Regional Cancer Center
-
West Des Moines, Iowa, United States, 50266-7700
- Methodist West Hospital
-
-
Kansas
-
Emporia, Kansas, United States, 66801
- Newman Regional Health
-
Garden City, Kansas, United States, 67846
- Central Care Cancer Center - Garden City
-
Garden City, Kansas, United States, 67846
- Saint Catherine Hospital
-
Great Bend, Kansas, United States, 67530
- Central Care Cancer Center - Great Bend
-
Great Bend, Kansas, United States, 67530
- Saint Rose Ambulatory and Surgery Center
-
Hays, Kansas, United States, 67601
- HaysMed University of Kansas Health System
-
Kansas City, Kansas, United States, 66160
- University of Kansas Cancer Center
-
Olathe, Kansas, United States, 66061
- Olathe Health Cancer Center
-
Overland Park, Kansas, United States, 66210
- University of Kansas Cancer Center-Overland Park
-
Pittsburg, Kansas, United States, 66762
- Ascension Via Christi - Pittsburg
-
Salina, Kansas, United States, 67401
- Salina Regional Health Center
-
Topeka, Kansas, United States, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, United States, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, United States, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, United States, 40202
- Norton Children's Hospital
-
Louisville, Kentucky, United States, 40207
- Norton Suburban Hospital and Medical Campus
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, United States, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, United States, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, United States, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, United States, 21215
- Sinai Hospital of Baltimore
-
Bethesda, Maryland, United States, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Cancer Center
-
Worcester, Massachusetts, United States, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- C S Mott Children's Hospital
-
Battle Creek, Michigan, United States, 49017
- Bronson Battle Creek
-
Brownstown, Michigan, United States, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, United States, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
Detroit, Michigan, United States, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, United States, 48236
- Ascension Saint John Hospital
-
East Lansing, Michigan, United States, 48824
- Michigan State University Clinical Center
-
Flint, Michigan, United States, 48503
- Hurley Medical Center
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids, Michigan, United States, 49503
- Helen DeVos Children's Hospital at Spectrum Health
-
Grand Rapids, Michigan, United States, 49503
- Trinity Health Grand Rapids Hospital
-
Jackson, Michigan, United States, 49201
- Allegiance Health
-
Kalamazoo, Michigan, United States, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, United States, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, United States, 49048
- Borgess Medical Center
-
Lansing, Michigan, United States, 48912
- Sparrow Hospital
-
Muskegon, Michigan, United States, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, United States, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Reed City, Michigan, United States, 49677
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, United States, 48073
- Beaumont Children's Hospital-Royal Oak
-
Saint Joseph, Michigan, United States, 49085
- Lakeland Medical Center Saint Joseph
-
Saint Joseph, Michigan, United States, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Traverse City, Michigan, United States, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, United States, 48322
- Henry Ford West Bloomfield Hospital
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
- Essentia Health Cancer Center
-
Minneapolis, Minnesota, United States, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Bolivar, Missouri, United States, 65613
- Central Care Cancer Center - Bolivar
-
Columbia, Missouri, United States, 65201
- Columbia Regional
-
Creve Coeur, Missouri, United States, 63141
- Siteman Cancer Center at West County Hospital
-
Joplin, Missouri, United States, 64804
- Freeman Health System
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospitals and Clinics
-
Kansas City, Missouri, United States, 64154
- University of Kansas Cancer Center - North
-
Kansas City, Missouri, United States, 64131
- The University of Kansas Cancer Center-South
-
Kansas City, Missouri, United States, 64132
- Research Medical Center
-
Lee's Summit, Missouri, United States, 64064
- University of Kansas Cancer Center - Lee's Summit
-
Rolla, Missouri, United States, 65401
- Delbert Day Cancer Institute at PCRMC
-
Rolla, Missouri, United States, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, United States, 63141
- Mercy Hospital Saint Louis
-
Saint Louis, Missouri, United States, 63104
- Cardinal Glennon Children's Medical Center
-
Springfield, Missouri, United States, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, United States, 65804
- Mercy Hospital Springfield
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, United States, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, United States, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, United States, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, United States, 89109
- GenesisCare USA - Las Vegas
-
Las Vegas, Nevada, United States, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, United States, 89148
- Comprehensive Cancer Centers of Nevada
-
Reno, Nevada, United States, 89502
- Renown Regional Medical Center
-
Reno, Nevada, United States, 89503
- Saint Mary's Regional Medical Center
-
Reno, Nevada, United States, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, United States, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, United States, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, United States, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, United States, 12208
- Albany Medical Center
-
Bronx, New York, United States, 10461
- Montefiore Medical Center-Einstein Campus
-
Bronx, New York, United States, 10467
- Montefiore Medical Center - Moses Campus
-
Bronx, New York, United States, 10461
- Montefiore Medical Center-Weiler Hospital
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
Glens Falls, New York, United States, 12801
- Glens Falls Hospital
-
Mineola, New York, United States, 11501
- NYU Winthrop Hospital
-
New Hyde Park, New York, United States, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
New York, New York, United States, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, United States, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, United States, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, United States, 14642
- University of Rochester
-
Syracuse, New York, United States, 13210
- State University of New York Upstate Medical University
-
Valhalla, New York, United States, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, United States, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, United States, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Greenville, North Carolina, United States, 27834
- East Carolina University
-
Matthews, North Carolina, United States, 28105
- Matthews Radiation Oncology Center
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, United States, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Children's Hospital Medical Center of Akron
-
Beachwood, Ohio, United States, 44122
- UHHS-Chagrin Highlands Medical Center
-
Beavercreek, Ohio, United States, 45431
- Indu and Raj Soin Medical Center
-
Centerville, Ohio, United States, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, United States, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
Cincinnati, Ohio, United States, 45242
- Oncology Hematology Care Inc-Blue Ash
-
Cincinnati, Ohio, United States, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, United States, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
Dayton, Ohio, United States, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, United States, 45409
- Miami Valley Hospital
-
Dayton, Ohio, United States, 45415
- Dayton Physician LLC-Miami Valley Hospital North
-
Dayton, Ohio, United States, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, United States, 45404
- Dayton Children's Hospital
-
Findlay, Ohio, United States, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, United States, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, United States, 45840
- Orion Cancer Care
-
Franklin, Ohio, United States, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, United States, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, United States, 45331
- Wayne Hospital
-
Greenville, Ohio, United States, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, United States, 45429
- Kettering Medical Center
-
Kettering, Ohio, United States, 45409
- Greater Dayton Cancer Center
-
Springfield, Ohio, United States, 45505
- Springfield Regional Medical Center
-
Springfield, Ohio, United States, 45504
- Springfield Regional Cancer Center
-
Toledo, Ohio, United States, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Troy, Ohio, United States, 45373
- Upper Valley Medical Center
-
Troy, Ohio, United States, 45373
- Dayton Physicians LLC - Troy
-
Wright-Patterson Air Force Base, Ohio, United States, 45433
- Wright-Patterson Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, United States, 73120
- Mercy Hospital Oklahoma City
-
Tulsa, Oklahoma, United States, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, United States, 97701
- Saint Charles Health System
-
Clackamas, Oregon, United States, 97015
- Clackamas Radiation Oncology Center
-
Coos Bay, Oregon, United States, 97420
- Bay Area Hospital
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
Portland, Oregon, United States, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, United States, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, United States, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, United States, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, United States, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, United States, 19134
- Saint Christopher's Hospital for Children
-
Philadelphia, Pennsylvania, United States, 19102
- Drexel University School of Medicine
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh of UPMC
-
Wynnewood, Pennsylvania, United States, 19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Boiling Springs, South Carolina, United States, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, United States, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, United States, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, United States, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, United States, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, United States, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, United States, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, United States, 29605
- BI-LO Charities Children's Cancer Center
-
Greenville, South Carolina, United States, 29605
- Prisma Health Greenville Memorial Hospital
-
Greenville, South Carolina, United States, 29601
- Greenville Health System Cancer Institute-Andrews
-
Greer, South Carolina, United States, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, United States, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, United States, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, United States, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, United States, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, United States, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, United States, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, United States, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, United States, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, United States, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, United States, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, United States, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, United States, 79415
- UMC Cancer Center / UMC Health System
-
Lubbock, Texas, United States, 79430
- Texas Tech University Health Sciences Center-Lubbock
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, United States, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, United States, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, United States, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, United States, 84113
- Primary Children's Hospital
-
South Jordan, Utah, United States, 84009
- South Jordan Health Center
-
-
Vermont
-
Berlin, Vermont, United States, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, United States, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, United States, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, United States, 23507
- Children's Hospital of The King's Daughters
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
Roanoke, Virginia, United States, 24014
- Carilion Children's
-
-
Washington
-
Aberdeen, Washington, United States, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, United States, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, United States, 98531
- Providence Regional Cancer System-Centralia
-
Everett, Washington, United States, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, United States, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, United States, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, United States, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, United States, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
Seattle, Washington, United States, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, United States, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, United States, 98112
- Kaiser Permanente Washington
-
Spokane, Washington, United States, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, United States, 98431
- Madigan Army Medical Center
-
Vancouver, Washington, United States, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, United States, 99362
- Providence Saint Mary Regional Cancer Center
-
Yakima, Washington, United States, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
- West Virginia University Charleston Division
-
Morgantown, West Virginia, United States, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Burlington, Wisconsin, United States, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Fond Du Lac, Wisconsin, United States, 54937
- Aurora Health Center-Fond du Lac
-
Germantown, Wisconsin, United States, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, United States, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, United States, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, United States, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Carbone Cancer Center
-
Marinette, Wisconsin, United States, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, United States, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, United States, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, United States, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, United States, 53233
- Aurora Sinai Medical Center
-
Milwaukee, Wisconsin, United States, 53226
- Children's Hospital of Wisconsin
-
Oshkosh, Wisconsin, United States, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, United States, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, United States, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, United States, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, United States, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha, Wisconsin, United States, 53188
- Aurora Cancer Care-Waukesha
-
Wauwatosa, Wisconsin, United States, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, United States, 53227
- Aurora West Allis Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Note: eligible patients must have a body surface area >= 0.5 m^2 AND be able to swallow whole tablets
Newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of the extremity and trunk will be eligible for the chemotherapy or non-chemotherapy cohort based on:
- Evidence of chemotherapy sensitivity of the histologic sarcoma subtype based on existing evidence from prior clinical trials
- Sufficient risk of metastatic disease to warrant chemotherapy based on size and grade and
- Medically deemed able or unable to undergo chemotherapy
- Notes: an incisional biopsy or core biopsy is preferred; fine needle aspiration biopsy is not acceptable to establish the diagnosis
ELIGIBLE SITES:
- Extremities: upper (including shoulder) and lower (including hip)
- Trunk: body wall
- INELIGIBLE SITES: Head and neck, visceral organs (with the exception of embryonal sarcoma of the liver), retroperitoneum, peritoneum, pelvis within the confines of the bony pelvis
- ELIGIBILITY FOR CHEMOTHERAPY COHORT:
- Stage T2a/b (> 5 cm) and grade 2 or 3 AND
One of the following chemosensitive histologies as defined in the World Health Organization (WHO) classification of soft tissue tumors (with some evidence of good response to chemoradiation and of sufficient high risk of metastases, or clear evidence of metastases):
- Unclassified soft tissue sarcomas that are too undifferentiated to be placed in a specific pathologic category in the WHO classification (often called "undifferentiated soft tissue sarcoma" or "soft tissue sarcoma not otherwise specified [NOS]")
- Synovial sarcoma
- Angiosarcoma of soft tissue
- Adult fibrosarcoma
- Mesenchymal (extraskeletal) chondrosarcoma
- Leiomyosarcoma
- Liposarcoma (excluding myxoid liposarcoma)
- Undifferentiated pleomorphic sarcoma
- Embryonal sarcoma of the liver
- Patients meeting the above criteria (histology, size, and grade) with the EXCEPTION of histologies noted above may enroll on the chemotherapy cohort or the non-chemotherapy cohort at the discretion of the enrolling investigator; patients meeting these criteria with the EXCEPTION of histologies noted above but medically deemed unable to receive chemotherapy or who elect not to receive chemotherapy are eligible for the non-chemotherapy cohort
Patients with the following histologies are only eligible for the chemotherapy cohort and cannot enroll on the non-chemotherapy cohort:
- Unclassified soft tissue sarcomas that are too undifferentiated to be placed in a specific pathologic category in the WHO classification (often called "undifferentiated soft tissue sarcoma" or "soft tissue sarcoma NOS") in patients < 30 years of age
- Synovial sarcoma
- Embryonal sarcoma of the liver
- ELIGIBILITY FOR NON-CHEMOTHERAPY COHORT:
Patients with any size of grade 2 or 3 of the following "intermediate (rarely metastasizing)" or "malignant" tumors, as defined in the WHO classification of soft tissue tumors for which we have consensus data of chemotherapy-resistance are eligible only for the non-chemotherapy cohort:
- So-called fibrohistiocytic tumors - plexiform fibrohistiocytic tumor, giant cell tumor of soft tissues
- Fibroblastic/myofibroblastic tumors - solitary fibrous tumor, malignant solitary fibrous tumor, inflammatory myofibroblastic tumor, low grade myofibroblastic sarcoma, myxoinflammatory fibroblastic sarcoma, atypical myxoinflammatory fibroblastic tumor, myxofibrosarcoma, low grade fibromyxoid sarcoma, sclerosing epithelioid fibrosarcoma
- Tumors of uncertain differentiation - epithelioid sarcoma, alveolar soft part sarcoma, clear cell sarcoma of soft tissue, angiomatoid fibrous histiocytoma, ossifying fibromyxoid tumor, myoepithelioma, myoepithelial carcinoma, extraskeletal myxoid chondrosarcoma, neoplasms with perivascular epithelioid cell differentiation (PEComa), intimal sarcoma, atypical fibroxanthoma, mixed tumor NOS, phosphaturic mesenchymal tumor, malignant ossifying fibromyxoid tumor, malignant mixed tumor, malignant phosphaturic mesenchymal tumor
- Chondro-osseous tumors - extraskeletal osteosarcoma
- Pericytic (perivascular) tumors - malignant glomus tumor
- Nerve sheath tumors - malignant peripheral nerve sheath tumor, malignant granular cell tumor, epithelioid malignant peripheral nerve sheath tumor, malignant Triton tumor
- Undifferentiated sarcomas (with a specific pathologic category in the WHO classification) - undifferentiated round cell sarcoma, undifferentiated epithelioid sarcoma, undifferentiated spindle cell sarcoma
- Patients meeting the criteria (histology, size, and grade) with the EXCEPTION of histologies noted above may enroll on the non-chemotherapy cohort at the discretion of the enrolling investigator; patients meeting these criteria with the EXCEPTION of histologies noted above but medically deemed unable to receive chemotherapy or who elect not to receive chemotherapy are eligible for the non-chemotherapy cohort; note that tumors arising in bone are NOT eligible for this study
Extent of disease:
- Patients with non-metastatic and metastatic disease are eligible
- Initially unresectable patients, with or without metastatic disease, are eligible as long as there is a commitment at enrollment to resect the primary tumor
- Sufficient tissue and blood must be available to submit for required biology studies
- Lansky performance status score >= 70 for patients =< 16 years of age
- Karnofsky performance status score >= 70 for patients > 16 years of age
- Absolute neutrophil count >= 1500/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
- Platelet count >= 100,000/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
- Hemoglobin >= 8 g/dL for patients =< 16 years of age; >= 9 g/dL for patients > 16 years of age; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or normal serum creatinine based on age/gender as follows:
- 2 to < 6 years; 0.8 mg/dL male; 0.8 mg/dL female
- 6 to < 10 years; 1 mg/dL male; 1 mg/dL female
- 10 to < 13 years; 1.2 mg/dL male; 1.2 mg/dL female
- 13 to < 16 years; 1.5 mg/dL male; 1.4 mg/dL female
- >= 16 years; 1.5 mg/dL male; 1.4 mg/dL female
- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age
- Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by radionuclide angiogram
- Corrected QT interval (QTc) < 480 msec
- No evidence of dyspnea at rest, no exercise intolerance, and a resting pulse oximetry reading > 94% on room air if there is clinical indication for determination
- Patients on low molecular weight heparin or Coumadin (with a stable international normalized ratio [INR]) are eligible
- Patient must have a life expectancy of at least 3 months with appropriate therapy
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
- Patients with grade 1 NRSTS tumors of any size are not eligible
- Patients with known central nervous system (CNS) metastases are not eligible; Note: brain imaging is not an eligibility requirement
- Patients with evidence of active bleeding or bleeding diathesis will be excluded (Note: patients aged > 17 years with excess of 2.5 mL of hemoptysis are not eligible)
- Patients with gross total resection of the primary tumor prior to enrollment on ARST1321 are NOT eligible; patients who have experienced tumor recurrence after a gross total tumor resection are NOT eligible
Patients with uncontrolled hypertension are ineligible; uncontrolled hypertension is defined as follows:
- Patients aged =< 17 years: greater than 95th percentile systolic and diastolic blood pressure based on age and height which is not controlled by one anti-hypertensive medication
- Patients aged > 17 years: systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg that is not controlled by one anti-hypertensive medication
Prior Therapy:
- Patients must have had no prior anthracycline (e.g., doxorubicin, daunorubicin) or ifosfamide chemotherapy
- Patients must have had no prior use of pazopanib or similar multi-targeted tyrosine kinase inhibitors (TKI)
- Patients must have had no prior radiotherapy to tumor-involved sites
- Note: patients previously treated for a non-NRSTS cancer are eligible provided they meet the prior therapy requirements; patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are excluded
- Other types of invasive malignancy that are not disease free within 3 years except for non-melanoma skin cancer, lentigo maligna, any carcinoma-in-situ or prostate cancer with low risk factors
- CYTOCHROME P450 3A4 (CYP3A4) substrates WITH narrow therapeutic indices: patients chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices within 7 days prior to study enrollment, including but not limited to pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; Note: the use of fentanyl is permitted
- CYP3A4 Inhibitors: patients chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment, including but not limited to itraconazole, clarithromycin, erythromycin many non-nucleoside reverse-transcriptase inhibitors (NNRTIs), diltiazem, verapamil, and grapefruit juice are not eligible
- CYP3A4 Inducers: patients chronically receiving drugs that are known potent CYP3A4 inducers within 14 days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifampin, and St. John's wort are not eligible (with the exception of glucocorticoids)
- Certain medications that are associated with a risk for QTc prolongation and/or Torsades de Pointes, although not prohibited, should be avoided or replaced with medications that do not carry these risks, if possible
Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:
- Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills
- Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel
- Active peptic ulcer disease
- Malabsorption syndrome
Subjects with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:
- Active peptic ulcer disease
- Known intraluminal metastatic lesions
- Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other gastrointestinal conditions which increase the risk of perforation
- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days prior to beginning study treatment
Subjects with any of the following cardiovascular conditions within the past 6 months
- Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
- Cardiac arrhythmia
- Admission for unstable angina
- Cardiac angioplasty or stenting
- Coronary artery bypass graft surgery
- Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been treated with therapeutic anticoagulation for less than 6 weeks
- Arterial thrombosis
- Symptomatic peripheral vascular disease
- Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; a subject who has a history of class II heart failure and is asymptomatic on treatment may be considered eligible
- History of serious or non-healing wound, ulcer, or bone fracture
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients who are unable to swallow whole tablets are not eligible
- Patients with a body surface area < 0.5 m^2 are not eligible
- Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with pazopanib; in addition, these subjects are at increased risk of lethal infections when treated with marrow-suppressive therapy
- Patients who are receiving any other investigational agent(s)
Pregnancy and breast feeding:
- Female patients who are pregnant are ineligible due to risks of fetal and teratogenic adverse events as seen in animal/human studies
- Lactating females are not eligible unless they have agreed not to breastfeed their infants during treatment and for a period of 1 month following completion of treatment
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
- Unwillingness to use an effective contraceptive method for the duration of their study participation and for at least 1 month after treatment is completed if sexually active with reproductive potential
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Regimen A (pazopanib, chemoradiation)
See Regimen A Detailed Description.
|
Given IV
Other Names:
Given PO
Other Names:
Undergo surgery
Given IV
Other Names:
Undergo radiation therapy
Other Names:
Given IV
Other Names:
Given PO
Other Names:
|
Experimental: Regimen B (chemoradiation)
See Regimen B Detailed Description.
|
Given IV
Other Names:
Undergo surgery
Given IV
Other Names:
Undergo radiation therapy
Other Names:
Given IV
Other Names:
|
Experimental: Regimen C (pazopanib, radiation therapy)
INDUCTION PHASE: Patients receive pazopanib PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7. SURGERY: Patients undergo surgery on week 10. CONTINUATION PHASE: Patients receive pazopanib PO QD on weeks 13-25. If applicable, patients undergo additional radiation therapy at week 13. |
Given PO
Other Names:
Undergo surgery
Undergo radiation therapy
Other Names:
Given PO
Other Names:
|
Experimental: Regimen D (radiation therapy)
INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7. SURGERY: Patients undergo surgery on week 10. CONTINUATION PHASE: If applicable, patients undergo additional radiation therapy at week 13. |
Undergo surgery
Undergo radiation therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasible Dose: Pediatric
Time Frame: After the first 6 weeks of Induction
|
The dose of pazopanib that is feasible when given in combination with radiation or chemoradiation in pediatric unresected intermediate- and high-risk NRSTS patients.
Initially, up to 10 patients (minimum of 3 patients ≥ 2 and < 18 years of age and 3 patients ≥ 18 years of age) eligible for each of the two study cohorts were non-randomly assigned (to generate 8 patients evaluable for toxicity) to receive treatment with pazopanib at dose level 1.
A protocol-defined list of pazopanib-associated adverse events were defined as dose-limiting toxicities.
The pazopanib dose determined to be feasible was based on the number of patient-reported dose-limiting toxicities encountered.
|
After the first 6 weeks of Induction
|
Feasible Dose: Adult
Time Frame: After the first 6 weeks of Induction
|
The dose of pazopanib that is feasible when given in combination with radiation or chemoradiation in adult unresected intermediate- and high-risk NRSTS patients.
Initially, up to 10 patients (minimum of 3 patients ≥ 2 and < 18 years of age and 3 patients ≥ 18 years of age) eligible for each of the two study cohorts were non-randomly assigned (to generate 8 patients evaluable for toxicity) to receive treatment with pazopanib at dose level 1.
A protocol-defined list of pazopanib-associated adverse events were defined as dose-limiting toxicities.
The pazopanib dose determined to be feasible was based on the number of patient-reported dose-limiting toxicities encountered.
|
After the first 6 weeks of Induction
|
Percentage of Chemoradiotherapy Patients With Positive Pathologic Response at Week 13
Time Frame: Week 13 after induction
|
A responder is defined by more than (90% tumor necrosis at week 13).
A non-responder has less than 90% necrosis or progressive disease before week 13.
|
Week 13 after induction
|
Percentage of Radiotherapy Patients With Positive Pathologic Response at Week 10
Time Frame: Week 10 after induction
|
A responder is defined by more than 90% tumor necrosis at week 10.
A non-responder has less than 90% necrosis or progressive disease before week 10.
|
Week 10 after induction
|
Percentage of Radiotherapy Patients Failure Free at 5 Years Following Study Entry
Time Frame: From enrollment to up to 60 months
|
Time to the first occurrence of relapse, progression, secondary cancer or death from any cause.
|
From enrollment to up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients Local Failure Free at 5 Years Following Study Entry
Time Frame: From enrollment to up to 60 months
|
Defined as disease recurrence only at the primary site of disease at diagnosis.
The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model.
|
From enrollment to up to 60 months
|
Percentage of Patients Regional Failure Free at 5 Years Following Study Entry
Time Frame: From enrollment to up to 60 months
|
Defined as disease recurrence at lymph nodes regional to the primary disease site, with or without local failure but without distant failure.
The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model.
|
From enrollment to up to 60 months
|
Percentage of Patients Distant Failure Free at 5 Years Following Study Entry
Time Frame: From enrollment to up to 60 months
|
Defined as disease recurrence at sites other than the primary site and diagnosis and nodes regional to that site (metastatic disease, whether or not present at diagnosis), with or without loco-regional failure.
The relative risk of specific failure types will be estimated and compared descriptively using the Cox proportional hazard model.
|
From enrollment to up to 60 months
|
Percentage of Patients Who Experienced Grade 3 or Higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame: Reporting of adverse events was required from the start of protocol therapy and until 30 days from the last administration of study drugs; up to 1 year
|
Participants who experienced Grade 3 or higher toxicity was assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
|
Reporting of adverse events was required from the start of protocol therapy and until 30 days from the last administration of study drugs; up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative Frequency of Actionable Mutations
Time Frame: At diagnosis
|
Descriptive statistical analyses will be provided to estimate the relative frequency of actionable mutations across the whole cohort and within more common histological subtypes, like synovial sarcoma and malignant peripheral nerve sheath tumors.
|
At diagnosis
|
Prevalence of Circulating Tumor DNA (ctDNA)
Time Frame: At diagnosis
|
Descriptive analyses will be performed to summarize the prevalence of ctDNA.
|
At diagnosis
|
Mean Pharmacokinetic Parameters of Doxorubicin and Pazopanib
Time Frame: Up to 48 hours after the end of infusion
|
Pharmacokinetic parameters such as the clearance of doxorubicin and pazopanib will be estimated.
|
Up to 48 hours after the end of infusion
|
Change in Fludeoxyglucose F 18 (FDG) Positron Emission Tomography (PET) Maximum Standard Uptake Value (SUVmax)
Time Frame: From enrollment to week 10 or 13 prior to tumor resection
|
To evaluate change in FDG PET maximum standard uptake value (SUVmax) from baseline to Week 10 or 13 in patients with unresected tumors and to correlate this change with pathologic response and EFS.
|
From enrollment to week 10 or 13 prior to tumor resection
|
Relative Risk of Failure Based on Both Standard Imaging and Pathologic Assessment
Time Frame: From enrollment up to 60 months
|
To compare the rate of response by standard imaging and pathologic assessment to determine which correlates better with local tumor control, distant tumor control, event free survival, and overall survival.
|
From enrollment up to 60 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aaron R Weiss, Children's Oncology Group
Publications and helpful links
General Publications
- Avutu V, Weiss AR, Reed DR, Ahmed SK, Allen-Rhoades WA, Chen YE, Davis LE, Eaton BR, Hawkins DS, Indelicato DJ, Patel SR, Randall RL, Reinke DK, Riedel RF, Scharschmidt TJ, Thornton KA, Wang D, Janeway KA, Kopp LM. Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. J Adolesc Young Adult Oncol. 2022 Jun;11(3):328-332. doi: 10.1089/jayao.2021.0103. Epub 2021 Sep 9.
- Weiss AR, Chen YL, Scharschmidt TJ, Chi YY, Tian J, Black JO, Davis JL, Fanburg-Smith JC, Zambrano E, Anderson J, Arens R, Binitie O, Choy E, Davis JW, Hayes-Jordan A, Kao SC, Kayton ML, Kessel S, Lim R, Meyer WH, Million L, Okuno SH, Ostrenga A, Parisi MT, Pryma DA, Randall RL, Rosen MA, Schlapkohl M, Shulkin BL, Smith EA, Sorger JI, Terezakis S, Hawkins DS, Spunt SL, Wang D. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020 Aug;21(8):1110-1122. doi: 10.1016/S1470-2045(20)30325-9. Epub 2020 Jul 20.
- Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neuromuscular Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Neoplasms, Vascular Tissue
- Neoplasms, Muscle Tissue
- Peripheral Nervous System Neoplasms
- Neoplasms, Adipose Tissue
- Neoplasms, Fibrous Tissue
- Neurofibroma
- Neoplasms
- Sarcoma
- Osteosarcoma
- Leiomyosarcoma
- Nerve Sheath Neoplasms
- Liposarcoma
- Chondrosarcoma
- Chondrosarcoma, Mesenchymal
- Neurofibrosarcoma
- Sarcoma, Synovial
- Sarcoma, Clear Cell
- Glomus Tumor
- Sarcoma, Alveolar Soft Part
- Histiocytoma, Malignant Fibrous
- Fibrosarcoma
- Histiocytoma
- Histiocytoma, Benign Fibrous
- Granular Cell Tumor
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Ifosfamide
- Isophosphamide mustard
- Doxorubicin
- Liposomal doxorubicin
- Daunorubicin
Other Study ID Numbers
- NCI-2014-01340 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA180886 (U.S. NIH Grant/Contract)
- U10CA180830 (U.S. NIH Grant/Contract)
- U10CA098543 (U.S. NIH Grant/Contract)
- ARST1321 (Other Identifier: CTEP)
- s14-02023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leiomyosarcoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingLocally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIC Uterine Corpus Leiomyosarcoma... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Uterine Corpus Leiomyosarcoma | Metastatic Uterine Corpus Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Uterine Corpus LeiomyosarcomaUnited States, Puerto Rico
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedUterus Leiomyosarcoma | Soft Tissue LeiomyosarcomaFrance
-
National Cancer Institute (NCI)Active, not recruitingStage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Uterine Corpus LeiomyosarcomaUnited States
-
Kristen GanjooRecruitingUterine Leiomyosarcoma | LMS - LeiomyosarcomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Liposarcoma | Unresectable LiposarcomaUnited States
-
David Liebner, MDWithdrawnLocally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Stage III Retroperitoneal Sarcoma AJCC v8 | Stage IIIA Retroperitoneal Sarcoma AJCC v8 | Stage IIIB Retroperitoneal Sarcoma AJCC v8 | Stage IV Retroperitoneal Sarcoma AJCC v8United States
-
Gachon University Gil Medical CenterMerck KGaA, Darmstadt, Germany; Chong Kun Dang Pharmaceutical Corp.RecruitingLeiomyosarcoma MetastaticKorea, Republic of
Clinical Trials on Ifosfamide
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupTerminatedChondrosarcoma | Adult Rhabdomyosarcoma | Adult Fibrosarcoma | Adult Leiomyosarcoma | Adult Malignant Meningioma | Adult Brain Malignant HemangiopericytomaUnited States, Australia, Peru, Puerto Rico
-
Yonsei UniversityRecruitingProstatic NeoplasmKorea, Republic of
-
Istituto Clinico HumanitasCompleted
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompletedSarcomaUnited States, South Africa
-
Institut Claudius RegaudSuspendedUnspecified Adult Solid Tumor, Protocol Specific | Chemotherapeutic Agent Toxicity | Renal ToxicityFrance
-
Oslo University HospitalScandinavian Sarcoma GroupUnknownSoft Tissue Sarcoma | Non Metastatic DiseaseSweden
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; Buddhist Tzu Chi... and other collaboratorsCompleted
-
Ludwig-Maximilians - University of MunichUnknownOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerGermany, Netherlands, Hungary
-
University Hospital MuensterHannover Medical School; Deutsche Kinderkrebsstiftung; Gesellschaft fur Padiatrische...UnknownIntracranial Germ Cell TumorsGermany
-
Tianjin Medical University Cancer Institute and...UnknownSoft Tissue SarcomaChina